Aspects of tranexamic acid use in patients with severe trauma


  • M.B. Vyshynska Danylo Halytsky Lviv National Medical University, Lviv, Ukraine



polytrauma, bleeding, tranexamic acid


Background. The article analyzes the impact of tranexamic acid use on the frequency of transfusion of blood components in patients with polytrauma. The purpose of our study was to find out the literature data on the use of tranexamic acid in patients with polytrauma and to analyze the frequency of blood components transfusion in patients with polytrauma, depending on time after injury onset. Materials and methods. We completed a retrospective cohort study and included 40 patients aged 22–56 years old with polytrauma. All patients were divi­ded into group I — those who received tranexamic acid up to 3 hours after the onset of polytrauma and group II — tranexamic acid was administered within 3–8 hours after the onset of polytrauma. Results. The main multifactorial factors which lead to early coagulopathy in patients with polytrauma are the combination of he­morrhagic shock and tissue injury, which leads to the generation of a thrombin-thrombomodulin complex, activation of anticoagulant and fibrinolytic systems. Among the patients included in the data analysis in our study, the main causes of polytrauma were: traffic accidents — in 34 patients (85 %), falls from a height — in 6 patients (15 %). The mean age of patients in group I was 39.2 ± 17.3 years, in group II — 41.9 ± 12.8 years (p = 0.23). The study included 29 men and 11 women. There were no significant differences in the injury severity, the components of multiple organ failure, and anthropometric characteristics in both groups. We found that in group I, transfusions of erythrocyte mass and fresh frozen plasma were performed in 14 cases out of 26 (53 % of all cases of polytrauma in this group). In group II blood transfusions were completed in 9 cases of 14 (64 % of all cases in this group). The rate of transfusion of blood components in group II was 11 % higher than in group I (p ≥ 0.05). Conclusions. Our preliminary findings indicate that the administration of tranexamic acid up to 3 hours after polytrauma may reduce the incidence of hemotransfusions.


Download data is not yet available.


Davenport RA. Activated protein C drives the hyperfibrinolysis of acute traumatic coagulopathy / Davenport RA, Guerreiro M, Frith D [et al] // Anesthesiology. – 2017. - 126(1) - 115-127.

Tarabrin O. How to control the coagulation disorders? Tarabrin O., Shcherbakov S., Gavrychenko D. [et al] // European Journal of Anaesthesiology. – 2013. - 30. -Suppl. 51:92

Hagemo JS. Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicenter observational study / Hagemo JS, Stanworth S, Juffermans NP [et al] // Crit Care. – 2014. - 18(2). - R52

Roberts I. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients / Roberts I., Shakur H., Coats T. [et al]. // Health Technol Assess. - 2013. - 17(10). - 1-79.

Pabinger I. Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis / Pabinger I., Fries D., Schоchl H., Streif W., Toller W. // Wien Klin Wochenschr. - 2017. - 129(9-10). - 303-316.

Roberts I. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial / Roberts I, Shakur H, Afolabi A, [et al]. // Lancet. – 2011. - 377(9771)/ - 1096–101 1101 e1091-1092. doi: 10.1016/S0140-6736(11)60278-X.

Spanh DF. The European guideline on management bleeding and coagulopathy following trauma: fifth edition / Spanh DF, Bouillon B, Cerny V,[ et al]. // Critical Care/ - 2019/

Gayet-Ageron A. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients / Gayet-Ageron A, Prieto-Merino D, Ker K, [et al]. // Lancet. – 2018/ - 391(10116). - 125–32.

Napolitano L. Tranexamic acid in trauma: how should we use it? / Napolitano L, Cohen M, Cotton B, Schreiber M, Moore E. // J Trauma Acute Care Surg. – 2013. - 74/ - 1575–86.

Ker K. Systematic review, metaanalysis and meta-regression of the effect of tranexamic acid on surgical blood loss/ Ker K, Prieto-Merino D, Roberts I.// B J Surg. – 2013. – 100. - 1271–9

Lowenstein CJ Regulation of Weibel-Palade body exocytosis / Lowenstein CJ, Morrell CN, Yamakuchi M. //Trends Cardiovasc Med. - 2005. – 15. - 302–8.

Neeki MM. Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study / Neeki MM, Dong F, Toy J [et al]. // West J Emerg Med. – 2017. - 18(4). - 673–683. doi:10.5811/westjem.2017.2.32044



How to Cite

Vyshynska, M. (2021). Aspects of tranexamic acid use in patients with severe trauma. EMERGENCY MEDICINE, 16(6), 85–88.



Original Researches